Investigation announced for Investors who lost money with shares of Theratechnologies Inc. (NASDAQ: THTX) over potential Wrongdoing

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Theratechnologies Inc.

Investors who purchased shares of Theratechnologies Inc. (NASDAQ: THTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Theratechnologies Inc. officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.

Canada based Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. Theratechnologies Inc. reported that its annual Total Revenue rose from $69.82 million in 2021 to $80.05 million in 2022, and that its Net Loss increased from $31.04 million in 2021 to$46.74 million in 2022.

On January 24, 2024, Theratechnologies issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) in response to the Company's supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin." The press release stated that "[t]he questions outlined in the CRL are largely related to chemistry, manufacturing and controls (CMC) concerning the microbiology, assays, impurities and stability for both the lyophilized product and the final reconstituted drug product. In addition, the FDA requested further information to understand the potential impact of the proposed formulation on immunogenicity risk."

Shares of Theratechnologies Inc. (NASDAQ: THTX) declined from $2.58 per share on January 08, 2024, to as low as $1.4 per share on January 24, 2024.

Those who purchased shares of Theratechnologies Inc. (NASDAQ: THTX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.